What is INMB stock price today?

INMB (Inmune Bio Inc) stock is trading at $1.18 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is INMB stock going up or down today?

INMB stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy INMB stock now?

The decision to buy INMB depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is INMB a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for INMB based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is INMB stock overvalued or undervalued?

Use our DCF valuation calculator to determine if INMB is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is INMB's P/E ratio?

P/E ratio data for INMB will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is INMB's market cap?

INMB (Inmune Bio Inc) has a market capitalization of $0.03 billion, making it a small-cap stock.

What is INMB's price to book ratio?

INMB trades at a price-to-book (P/B) ratio of 1.33, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does INMB pay dividends?

INMB does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is INMB's dividend yield?

INMB does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is INMB stock a good long-term investment?

INMB's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is INMB's revenue growth rate?

INMB has shown revenue growth of 2.6% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for INMB are available on our dashboard with complete income statement analysis.

What are the risks of investing in INMB?

Key risks for INMB include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does INMB compare to its competitors?

Compare INMB to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize INMB's performance and positioning.

What is INMB's stock price target for 2026?

Our AI model provides price targets for INMB based on fundamental analysis: Bull case $1.53 (+30%), Base case $1.36 (+15%), Bear case $1.06 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about INMB?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for INMB. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is INMB's next earnings report?

INMB reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

INMB - Inmune Bio Inc

NYSE * Health Care * Biotechnology

$1.18

$-0.10 (-7.81%)

About Inmune Bio Inc

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INMB Key Statistics

Market Cap

$31.37M

P/B Ratio

1.33

EPS

$-1.86

Revenue Growth

+2.6%

Employees

How INMB Compares to Peers

INMB has the fastest revenue growth among competitors

INMB is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
INMB(This stock)	$31.37M	N/A	3%	0.0%	-
AMGNAmgen Inc	$189.19B	24.7	0%	0.2%	vs AMGN
GILDGilead Sciences	$174.33B	20.7	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.01B	29.0	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.87B	18.2	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.26B	20.4	-0%	0.1%	vs BIIB

Inmune Bio Inc Company Information

Headquarters: California; U.S.A
Website: www.inmunebio.com
Sector: Health Care
Industry: Biotechnology

INMB - Inmune Bio Inc

About Inmune Bio Inc

INMB Key Statistics

How INMB Compares to Peers

Inmune Bio Inc Company Information

INMB Lician Score

INMB Financial Snowflake

Upcoming Events for INMB